Chapter 9 212 REFERENCES 1. Arlett P, Kjær J, Broich K, Cooke E. Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value. Clin Pharmacol Ther. 2022;111(1):21-23. doi:10.1002/cpt.2479 2. Viele K, Berry S, Neuenschwander B, et al. Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat. 2014;13(1):41-54. doi:10.1002/pst.1589 3. FDA. Rare Diseases: Natural History Studies for Drug Development | FDA.; 2019. https://www. fda.gov/regulatory-information/search-fdaguidance-documents/rare-diseases-naturalhistory-studies-drug-development 4. Pocock SJ. The combination of randomized and historical controls in clinical trials. J Chronic Dis. 1976;29(3):175-188. doi:10.1016/00219681(76)90044-8 5. Hatswell A, Freemantle N, Baio G, Lesaffre E, van Rosmalen J. Summarising salient information on historical controls: A structured assessment of validity and comparability across studies. Clin Trials. 2020;17(6):607-616. doi:10.1177/1740774520944855 6. Galwey NW. Supplementation of a clinical trial by historical control data: is the prospect of dynamic borrowing an illusion? Stat Med. 2017;36(6):899-916. doi:10.1002/sim.7180 7. van Rosmalen J, Dejardin D, van Norden Y, Löwenberg B,Lesaffre E.Including historical data in the analysis of clinical trials: Is it worth the effort? Stat Methods Med Res. 2018;27(10):31673182. doi:10.1177/0962280217694506 8. Neuenschwander B, Roychoudhury S, Schmidli H. On the Use of Co-Data in Clinical Trials. Stat Biopharm Res. 2016;8(3):345-354. doi:10.1080/ 19466315.2016.1174149 9. Freidlin B, Korn EL. Augmenting randomized clinical trial data with historical control data: Precision medicine applications. JNCI J Natl Cancer Inst. 2023;115(1):14-20. doi:10.1093/jnci/djac185 10. Kopp-Schneider A, Calderazzo S, Wiesenfarth M. Power gains by using external information in clinical trials are typically not possible when requiring strict type I error control. Biom J. 2020;62(2):361-374. doi:10.1002/ bimj.201800395 11. Lewis CJ, Sarkar S, Zhu J, Carlin BP. Borrowing from Historical Control Data in Cancer Drug Development: A Cautionary Tale and Practical Guidelines. Stat Biopharm Res. 2019;11(1):67-67. doi:10.1080/19466315.2018.1497533 12. FDA. Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials. Published online February 5, 2010. https://www.fda.gov/ media/71512/download 13. Best N, Price RG, Pouliquen IJ, Keene ON. Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing. Pharm Stat. 2021;20(3):551562. doi:10.1002/pst.2093 14. Liu M, Bunn V, Hupf B, Lin J, Lin J. Propensityscore-based meta-analytic predictive prior for incorporating real-world and historical data. Stat Med. 2021;40(22):4794-4808. doi:10.1002/ SIM.9095 15. Schmidli H, Gsteiger S, Roychoudhury S, O’Hagan A, Spiegelhalter D, Neuenschwander B. Robust meta-analytic-predictive priors in clinical trials with historical control information. Biometrics. 2014;70(4):1023-1032. doi:10.1111/ biom.12242 16. Hobbs BP, Carlin BP, Mandrekar SJ, Sargent DJ. Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials. Biometrics. 2011;67(3):1047-1056. doi:10.1111/j.15410420.2011.01564.x 17. Hobbs BP, Sargent DJ, Carlin BP. Commensurate priors for incorporating historical information in clinical trials using general and generalized linear models. Bayesian Anal. 2012;7(3):639674. doi:10.1214/12-BA722 18. Nikolakopoulos S, van der Tweel I, Roes KCB. Dynamic borrowing through empirical power priors that control type I error. Biometrics. 2018;74(3):874-880. doi:10.1111/biom.12835 19. Banbeta A, van Rosmalen J, Dejardin D, Lesaffre E. Modified power prior with multiple historical trials for binary endpoints. Stat Med. 2019;38(7):1147-1169. doi:10.1002/sim.8019
RkJQdWJsaXNoZXIy MTk4NDMw